News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merck & Co., Inc. (MRK) Release: Patients with Type 2 Diabetes Fasting for Ramadan in India and Malaysia Were About Half as Likely to Experience Low Blood Sugar When Switched from a Sulfonylurea to MSD’s JANUVIA® (sitagliptin)



6/28/2012 9:48:51 AM

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--A new study published today in Current Medical Research & Opinion (CMRO) showed that people with type 2 diabetes who chose to fast during Ramadan and were switched to MSD’s JANUVIA (sitagliptin) from a sulfonylurea (SU) experienced approximately half the risk of symptomatic low blood sugar (hypoglycemia) compared to patients who maintained treatment with an SU (n=16/421 [3.8%] versus n=31/427 [7.3%]). A total of 85 episodes of symptomatic hypoglycemia were reported in both groups. In the sitagliptin group, 22 episodes were reported by 16 patients, and in the SU group, 63 episodes were reported by 31 patients.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES